PPMI specifications

Information


Unique identifier OMICS_25875
Name PPMI
Alternative name Parkinson Progression Marker Initiative
Restrictions to use None
Community driven No
Data access Browse
User data submission Not allowed
Registration required Yes
Maintained Yes

Maintainer


  • person_outline Leslie Shaw

Additional information


http://www.ppmi-info.org/about-ppmi/

Publications for Parkinson Progression Marker Initiative

PPMI institution(s)
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Pharmacology, Hypoxia-related Disease Research Center, Inha University School of Medicine, Incheon, South Korea; Paracelsus-Elena Klinik, Kassel, Germany; Department of Neuropathology and Neurosurgery, University Medical Center Goettingen, Gottingen, Germany; Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA; Center for Neurodegenerative Disease Research, Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Neurology, Morris K. Udall Center of Excellence for Parkinson’s Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Veterans Affairs, Philadelphia, PA, USA; Department of Neurosciences, University of California, San Diego, CA, USA; BioLegend Inc., Dedham, MA, USA; The Michael J. Fox Foundation for Parkinson’s Research, New York, NY, USA; Institute for Neurodegenerative Disorders, New Haven, CT, USA; Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; University of California-San Francisco and San Francisco Veteran’s Affairs Medical Center, San Francisco, CA, USA; Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Molecular Genetics Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA; Laboratory of Neuro Imaging, The Institute for Neuroimaging and Informatics, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, USA
PPMI funding source(s)
Supported by The Michael J. Fox Foundation for Parkinson’s Research, Abbott, Avid Radiopharmaceuticals, BiogenIdec, Covance, Elan, Eli Lilly and Co, F. Hoffman-LaRoche Ltd, GE Healthcare, Genentech, Glaxo Smith Kline, Merck and Co, Pfizer Inc, and UCB Pharma SA; by core grant P50NS053488-05 from the Morris K. Udall Center of Excellence for Parkinson’s Disease Research; by Training in Age-Related Neurodegenerative Diseases grant T32-AG000255 from the National Institute on Aging, National Institutes of Health; by Grant Z01AG000949-06 from the Intramural Research Program, National Institute on Aging, National Institutes of Health; by Grant MRC 2014009392 from the National Research Foundation of Korea, Ministry of Science, ICT and Future Planning; by grants and/or research support from the National Eye Institute, National Institute of Neurological Disorders and Stroke, National Institute on Aging, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Neurosearch, and Medication; by grants and/or research support from Brin Foundation, James and Sharron Clark, Parkinson’s Institute and Clinical Center, Parkinson’s Disease Foundation, US Army Medical Research Acquisition Activity (Telemedicine and Advanced Technology Research Center—managed Neurotoxin Exposure Treatment Research Program), National Institute of Neurological Disorders and Stroke, Agency for Healthcare and Research Quality, and National Institute of Environmental Health Sciences; and by the National Institutes of Health, and the Alzheimer’s Drug Discovery Foundation.

PPMI reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review PPMI